FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985502087> ?p ?o ?g. }

• W1985502087 endingPage "1729" @default.
• W1985502087 startingPage "1721" @default.
• W1985502087 abstract "1 In the dog saphenous vein α1- and α2-adrenoceptors mediate noradrenaline-induced contractions in vitro. In order to study the α2-adrenoceptor in isolation, α1-adrenoceptors were inactivated by treatment of tissues with the alkylating agent phenoxybenzamine (3.0 μM for 30 min) in the presence of rauwolscine (1 μM) to protect α2-adrenoceptors. 2 Noradrenaline-induced contractions of tissues treated with phenoxybenzamine were antagonized competitively by the selective α2-adrenoceptor antagonist rauwolscine, pKB=8.63±0.07 (means±s.e.mean; n=3), consistent with an interaction at α2-adrenoceptors. 3 Noradrenaline was a full agonist at α2-adrenoceptors in dog saphenous vein. By use of the method of partial receptor alkylation and analysis of concentration-effect curve data by direct, operational model fitting methods, the affinity (pKA) and efficacy (τ) were 5.74±0.07 and 7.50±1.05, respectively (n=6). Nine other agonists which were examined each had affinities higher than noradrenaline, but with the exception of the imidazoline, A-54741 (5,6-dihydroxy-1,2,3,4-tetrahydro-1-naphthyl-imidazoline) had relatively lower efficacies. 4 To compare the α2-adrenoceptor in dog saphenous vein to the human recombinant subtypes, the affinities of twenty-one compounds were estimated in functional studies in the dog saphenous vein and in radioligand binding studies for the human α2A, α2B and α2C receptor subtypes expressed in Chinese hamster lung (CHL) cells. 5 Of twenty-one compounds examined in ligand binding studies, only nine had greater than ten fold selectivity for one human receptor subtype over either of the other two. These compounds were A-54741, oxymetazoline, guanfacine, guanabenz, prazosin, spiroxatrine, tolazoline, WB 4101 and idazoxan. In dog saphenous vein, their affinities (pKA and pKB for agonists and antagonists respectively) were: A-54741 (pKA=8.03±0.05), oxymetazoline (pKA=7.67±0.09), guanfacine (pKA=6.79±0.03); guanabenz (pKA=7.02±0.13); prazosin (pKB=5.19±0.08), spiroxatrine (pKB=6.59±0.04), tolazoline (pKB=6.21±0.07), WB 4101 (pKB=7.42±0.09) and idazoxan (pKB=7.11±0.08). 6 Comparisons of affinity estimates for these nine compounds at the receptor in dog saphenous vein and at the human recombinant subtypes suggest that the vascular receptor is most similar to the h α2A subtype; correlation coefficients (r) were 0.82 (h α2A), 0.24 (h α2B) and 0.04 (h α2C). British Journal of Pharmacology (1997) 121, 1721–1729; doi:10.1038/sj.bjp.0701296" @default.
• W1985502087 created "2016-06-24" @default.
• W1985502087 creator A5026881566 @default.
• W1985502087 creator A5062111743 @default.
• W1985502087 creator A5063940122 @default.
• W1985502087 creator A5072070682 @default.
• W1985502087 creator A5089786161 @default.
• W1985502087 date "1997-08-01" @default.
• W1985502087 modified "2023-09-27" @default.
• W1985502087 title "Characterization of<i>α</i>₂-adrenoceptors mediating contraction of dog saphenous vein: identity with the human<i>α</i>_2Asubtype" @default.
• W1985502087 cites W1519213675 @default.
• W1985502087 cites W1592358009 @default.
• W1985502087 cites W1973019381 @default.
• W1985502087 cites W1982324672 @default.
• W1985502087 cites W1986786203 @default.
• W1985502087 cites W1988298211 @default.
• W1985502087 cites W1993312669 @default.
• W1985502087 cites W1994819764 @default.
• W1985502087 cites W1998320010 @default.
• W1985502087 cites W1998610166 @default.
• W1985502087 cites W2009087137 @default.
• W1985502087 cites W2023665876 @default.
• W1985502087 cites W2025267941 @default.
• W1985502087 cites W2038361574 @default.
• W1985502087 cites W2041873555 @default.
• W1985502087 cites W2043687239 @default.
• W1985502087 cites W2050794064 @default.
• W1985502087 cites W2066482395 @default.
• W1985502087 cites W2066622502 @default.
• W1985502087 cites W2067559316 @default.
• W1985502087 cites W2069146882 @default.
• W1985502087 cites W2074631079 @default.
• W1985502087 cites W2080202671 @default.
• W1985502087 cites W2084235775 @default.
• W1985502087 cites W2091747024 @default.
• W1985502087 cites W2949552926 @default.
• W1985502087 doi "https://doi.org/10.1038/sj.bjp.0701296" @default.
• W1985502087 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1564855" @default.
• W1985502087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9283709" @default.
• W1985502087 hasPublicationYear "1997" @default.
• W1985502087 type Work @default.
• W1985502087 sameAs 1985502087 @default.
• W1985502087 citedByCount "38" @default.
• W1985502087 countsByYear W19855020872012 @default.
• W1985502087 countsByYear W19855020872013 @default.
• W1985502087 countsByYear W19855020872014 @default.
• W1985502087 countsByYear W19855020872015 @default.
• W1985502087 countsByYear W19855020872018 @default.
• W1985502087 countsByYear W19855020872020 @default.
• W1985502087 countsByYear W19855020872021 @default.
• W1985502087 crossrefType "journal-article" @default.
• W1985502087 hasAuthorship W1985502087A5026881566 @default.
• W1985502087 hasAuthorship W1985502087A5062111743 @default.
• W1985502087 hasAuthorship W1985502087A5063940122 @default.
• W1985502087 hasAuthorship W1985502087A5072070682 @default.
• W1985502087 hasAuthorship W1985502087A5089786161 @default.
• W1985502087 hasBestOaLocation W19855020872 @default.
• W1985502087 hasConcept C123605464 @default.
• W1985502087 hasConcept C126322002 @default.
• W1985502087 hasConcept C134018914 @default.
• W1985502087 hasConcept C170493617 @default.
• W1985502087 hasConcept C185592680 @default.
• W1985502087 hasConcept C2776504411 @default.
• W1985502087 hasConcept C2776885963 @default.
• W1985502087 hasConcept C2778938600 @default.
• W1985502087 hasConcept C2780648677 @default.
• W1985502087 hasConcept C2780668150 @default.
• W1985502087 hasConcept C67847695 @default.
• W1985502087 hasConcept C71924100 @default.
• W1985502087 hasConcept C86803240 @default.
• W1985502087 hasConcept C98274493 @default.
• W1985502087 hasConceptScore W1985502087C123605464 @default.
• W1985502087 hasConceptScore W1985502087C126322002 @default.
• W1985502087 hasConceptScore W1985502087C134018914 @default.
• W1985502087 hasConceptScore W1985502087C170493617 @default.
• W1985502087 hasConceptScore W1985502087C185592680 @default.
• W1985502087 hasConceptScore W1985502087C2776504411 @default.
• W1985502087 hasConceptScore W1985502087C2776885963 @default.
• W1985502087 hasConceptScore W1985502087C2778938600 @default.
• W1985502087 hasConceptScore W1985502087C2780648677 @default.
• W1985502087 hasConceptScore W1985502087C2780668150 @default.
• W1985502087 hasConceptScore W1985502087C67847695 @default.
• W1985502087 hasConceptScore W1985502087C71924100 @default.
• W1985502087 hasConceptScore W1985502087C86803240 @default.
• W1985502087 hasConceptScore W1985502087C98274493 @default.
• W1985502087 hasIssue "8" @default.
• W1985502087 hasLocation W19855020871 @default.
• W1985502087 hasLocation W19855020872 @default.
• W1985502087 hasLocation W19855020873 @default.
• W1985502087 hasLocation W19855020874 @default.
• W1985502087 hasOpenAccess W1985502087 @default.
• W1985502087 hasPrimaryLocation W19855020871 @default.
• W1985502087 hasRelatedWork W1578204675 @default.
• W1985502087 hasRelatedWork W1985502087 @default.
• W1985502087 hasRelatedWork W2003193331 @default.
• W1985502087 hasRelatedWork W2003896488 @default.
• W1985502087 hasRelatedWork W2020172590 @default.
• W1985502087 hasRelatedWork W2050794064 @default.

• next